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Abstract
Transmissible spongiform encephalopathies are characterized by the accumulation of PrPSc, a
protease-resistant form of a host-derived protein termed PrPC. Substantial evidence indicates that PrPSc
represents an essential component of the infectious agent, which is termed prion. The accumulation of
PrPSc within the central nervous system of prion-infected organisms is a dynamic process that is
regulated both by production and by clearance of PrPSc. Although several proteases have been
implicated in proteolysis of PrPC, the mechanisms underlying proteolysis of PrPSc remain unclear.
Here, it was investigated whether neprilysin, a metalloprotease known to degrade extracellular
amyloidogenic proteins such as amyloid-beta, plays a role in prion pathogenesis in vivo. As neprilysin
has a broad substrate specificity and is localized subcellularly in the vicinity of PrP, it represents a
plausible candidate for prion degradation. Prions were therefore administered to mice lacking or
overexpressing neprilysin in brain. However, the gene dosage of neprilysin did not modulate
accumulation of PrPSc in brain. Also, incubation times and clinical course of prion disease, as well as
brain infectivity titres at terminal stage, were unaffected. These data rule out neprilysin as a major
modulator of PrPSc accumulation and prion pathogenesis.
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Transmissible spongiform encephalopathies are characterized by the accumulation of PrPSc, a
protease-resistant form of a host-derived protein termed PrPC. Substantial evidence indicates that
PrPSc represents an essential component of the infectious agent, which is termed prion. The
accumulation of PrPSc within the central nervous system of prion-infected organisms is a
dynamic process that is regulated both by production and by clearance of PrPSc. Although several
proteases have been implicated in proteolysis of PrPC, the mechanisms underlying proteolysis
of PrPSc remain unclear. Here, it was investigated whether neprilysin, a metalloprotease
known to degrade extracellular amyloidogenic proteins such as amyloid-b, plays a role in prion
pathogenesis in vivo. As neprilysin has a broad substrate specificity and is localized subcellularly
in the vicinity of PrP, it represents a plausible candidate for prion degradation. Prions were
therefore administered to mice lacking or overexpressing neprilysin in brain. However, the gene
dosage of neprilysin did not modulate accumulation of PrPSc in brain. Also, incubation times
and clinical course of prion disease, as well as brain infectivity titres at terminal stage, were
unaffected. These data rule out neprilysin as a major modulator of PrPSc accumulation and prion
pathogenesis.
INTRODUCTION
Transmissible spongiform encephalopathies are neuro-
degenerative diseases that are characterized by the deposi-
tion of PrPSc, an abnormal, relatively protease-resistant
isomer of a normal host-encoded cellular glycoprotein
termed PrPC. Prion infectivity copurifies with PrPSc, sug-
gesting that this abnormal isomer is a component of the
infectious agent (Aguzzi & Polymenidou, 2004). There are
no differences in primary structure between PrPC and PrPSc.
Formation of PrPSc is thought to result from the conversion
of PrPC to PrPSc and its subsequent aggregation. The details
of this process are not understood (Aguzzi & Polymenidou,
2004).
Formally, the accumulation of PrPSc in brain and extra-
neural organs is the result of the differential between its de
novo generation and its clearance. Surprisingly, clearance of
PrPSc is exceedingly efficient in vivo. Very large amounts of
PrPSc injected into brain or peritoneum of Prnp-deficient
mice (Bu¨eler et al., 1992), which are incapable of replicating
prions, resulted in a very fast decrease to concentrations
below detectability (Bu¨eler et al., 1993).
Although the relative resistance of PrPSc to protease diges-
tion is the basis of laboratory assays for prion infections, it is
obvious that PrPSc undergoes proteolytic processing in cell-
culture models of prion diseases and in vivo (Bu¨eler et al.,
1993; Enari et al., 2001; Glatzel et al., 2003). Proteolytic
processing of PrPC and PrPSc differs and cleavage of PrPSc
may lead to the occurrence of a 20 kDa PrPSc fragment
referred to as C2, whereas cleavage of PrPC leads to the
formation of an 18 kDa fragment termed C1 (Chen et al.,
1995; Jime´nez-Huete et al., 1998). Although protein kinase
C-dependent cleavage of PrPC by ADAM10 and TACE has
been reported, the protease responsible for PrPSc cleavage
remains enigmatic (Checler & Vincent, 2002; Vincent et al.,
2001). It was suggested that the alleged PrPSc-processing
protease could belong to the metalloprotease family of
enzymes, yet no studies have been undertaken until now to
address the exact nature of this activity (Jime´nez-Huete et al.,
1998).
Neprilysin, a zinc metalloprotease, has been shown to cata-
bolize neurotoxic amyloid-b protein that accumulates in
Alzheimer’s disease (Iwata et al., 2001;Mohajeri et al., 2004).
The localization of neprilysin, a type II integral membrane
protein, the relatively broad substrate specificity of this3These authors contributed equally to this work.
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peptidase and the amyloid-b-degrading properties suggest
a possible involvement of neprilysin in PrPC/PrPSc catabo-
lism (Turner, 2003). Involvement of neprilysin in degrada-
tion of aggregated PrPSc is further supported by similarities
between PrPSc and amyloid-b. Both proteins are deposited
in the extracellular space in the form of amyloid and both
proteins may act as neurotoxins, either as aggregates or in
the form of soluble oligomers (Aguzzi & Haass, 2003).
Here, we investigated whether PrPC or PrPSc represents a
substrate for the enzymic activity of neprilysin by exposing
mice (i) entirely lacking neprilysin, (ii) expressing reduced
amounts of neprilysin or (iii) overexpressing neprilysin, to
infectious prions.
METHODS
Generation and husbandry of transgenic mice. Neprilysin-
deficient mice were described previously (Lu et al., 1995). Gene-
tically modified mice overexpressing neprilysin in the central
nervous system (CNS) were generated by following this strategy: a
haemagglutinin tag was fused in frame with the C terminus of
human neprilysin cDNA (Shirotani et al., 2001). This fragment was
then inserted into the XhoI site of the MoPrP expression vector
(Borchelt et al., 1996). Transgenic mice were generated by standard
pronuclear injection of the DNA construct into (C57BL/66DBA/2)
F1 embryos. The presence of the transgene was confirmed by PCR
analysis of genomic DNA isolated from tail biopsies by using pri-
mers 59-CAGAACTGAACCATTTCAAC-39 and 59-CTATGATGG-
TGAGGAGCAGGACAAG-39, which were specific for the transgene.
Transgenic founders were mated to C57BL/6 mice and one trans-
genic line, designated Nep-tg, was established from the F1 progeny
on a mixed C57BL/66DBA/2 background. All animal experiments
and animal husbandry were performed in compliance with national
guidelines.
Measurement of the Nep peptidase activity. Neprilysin enzyme
activity was measured in brain homogenates of Nep-tg (n=4) and
wild-type (wt) littermates (n=4) as described previously, with
minor modifications (Shirotani et al., 2001). In brief, 34 mg protein
homogenized in 150 mM NaCl, 100 mM Tris/HCl, 1% Triton X-
100 (pH 7?8) was incubated for 1 h at 37 uC with 100 mM Z-Ala-
Ala-Leu-p-nitroanilide (ZAAL-pNA; Bachem) in 50 mM HEPES
buffer (pH 7?2). Thereafter, 0?8 mU leucine aminopeptidase (Sigma)
was added to the reaction mixtures, incubated for an additional
20 min at 37 uC (Mohajeri et al., 2004) and OD405 was measured. To
inhibit neprilysin activity, 40 mM thiorphan (Sigma) was added for
5 min at room temperature before the addition of ZAAL-pNA. The
results were confirmed by measuring several amounts of the Nep-tg
samples diluted in similarly prepared brain homogenate of a Nep-KO
mouse that exhibits no neprilysin enzyme activity (data not shown).
Scrapie infections. Mice were infected intraperitoneally (i.p.)
with 100 ml brain homogenate diluted in PBS and containing 6 or 3
logLD50 intracerebral (i.c.) units of the Rocky Mountain laboratory
(RML) scrapie strain (passage 5). For i.c. inoculations, 30 ml inocu-
lum with 36105 or 36102 LD50 i.c. units was administered. Mice
were monitored every second day and scrapie was diagnosed accord-
ing to standard clinical criteria. Mice were sacrificed on the day of
onset of terminal clinical signs of scrapie. The data for terminal
disease are given as means±SD.
Infectivity bioassay with tga20 indicator mice. Assays were
performed on 1% (w/v) brain homogenates. Tissues were homoge-
nized in 0?32 M sucrose with a microhomogenizer (TreffLab)
diluted in PBS/5% BSA. When the solution appeared homo-
geneous, it was spun for 5 min at 500 g. Supernatants (30 ml) were
inoculated i.c. into groups of five or six tga20 mice (Fischer et al.,
1996). Incubation time until development of terminal scrapie sick-
ness was determined and infectivity titres were calculated for 1 g
inoculated tissue by using the relationship y=11?4520?088x, where
y is the number of i.c. LD50 units and x is the incubation time
(days) to terminal disease (Prusiner et al., 1982).
Western blot analysis. Brain homogenates were adjusted to
8 mg protein ml21 and treated with proteinase K where indicated
(50 mg ml21, 30 min, 37 uC). Total protein (50 mg) was electrophor-
esed through an SDS-PAGE gel (12%). Proteins were transferred
to nitrocellulose by wet blotting. Membranes were blocked with
Tris/HCl-buffered saline/Tween 20 (TBST) containing 5% Top
Block, pH 7?4 (Sigma), incubated with mAb POM 1 to PrP (M.
Polymenidou, M. Vey & A. Aguzzi, unpublished data) or with mAb
56C6 to neprilysin (Novocastra) and visualized by enhanced chemi-
luminescence (ECL; Amersham Biosciences) (Glatzel et al., 2001).
Histology and immunohistochemistry. Paraffin-embedded
sections from brain were stained with haematoxylin and eosin.
Immunostaining to glial fibrillary acidic protein (GFAP) was per-
formed with a rabbit antiserum against GFAP (1 : 300 dilution;
DAKO) and detected with biotinylated swine anti-rabbit serum
(1 : 250 dilution; DAKO) and diaminobenzidine (Sigma).
Histoblots. Histoblots were performed according to Taraboulos
et al. (1992). Briefly, frozen sections were mounted on uncoated
glass slides and pressed immediately on a nitrocellulose membrane
wetted in lysis buffer. Membranes were air-dried for at least 24 h.
For detection, they were rehydrated in TBST and limited proteo-
lysis was performed by using proteinase K concentrations of 50 and
100 mg ml21 at 37 uC for 4 h. Blots were then denatured in 3 M
guanidinium thiocyanate for 10 min and blocked for 1 h in 5%
non-fat milk. Incubation with primary antibody XN to PrP was
carried out at a dilution of 1 : 2000 in 1% non-fat milk at room
temperature for 1 h (Glatzel & Aguzzi, 2000). Detection was accom-
plished with an alkaline phosphatase-conjugated goat anti-mouse
antibody (1 : 2000). Visualization was achieved with nitro blue tetra-
zolium and BCIP according to the protocols of the supplier (Sigma).
RESULTS
Overexpression of neprilysin in the CNS of
Nep-tg mice
In order to overexpress neprilysin in the CNS, we prepared a
DNA construct in which the coding region of the human
neprilysin gene was fused to a haemagglutinin tag, placed
under the transcriptional control of the murine prion
protein promoter and injected into the pronuclei of C57BL/
66DBA/2 zygotes (Fig. 1a).
Transgenic founders were identified by PCR analysis and
were bred to C57BL/6 mice. Transgene expression in the
resulting mouse colony (mixed C57BL/66DBA/2) was
analysed in brain homogenates of 12-week-old F1 offspring.
All subsequent analyses were performed with heterozygous
offspring of one line (designated Nep-tg). Western blot
analysis of total brain homogenates showed approximate-
ly 50-fold overexpression of neprilysin (Fig. 1b) and a
34-fold higher enzyme activity of neprilysin (Fig. 1c) in
Nep-tg mice compared with wt controls.
1862 Journal of General Virology 86
M. Glatzel and others
PrPC is not a substrate for the enzymic activity
of neprilysin
Because of the relatively broad substrate specificity of
neprilysin, we investigated whether PrPC might represent a
substrate for degradation by neprilysin (Turner, 2003). If
this were correct, one would expect decreased protein levels
of PrPC in mice overexpressing neprilysin. Conversely, the
complete lack of neprilysin expression in neprilysin-
knockout mice could lead to increased protein levels of
PrPC in these mice.
In order to test these possibilities, we assessed the relative
quantities of PrPC in mice overexpressing and lacking
neprilysin by Western blot analysis (Fig. 1d). There were no
significant alterations of PrPC protein levels between these
transgenic lines of mice and appropriate wt controls, as
evidenced by the ratios of the signal intensities of PrPC to
corresponding b-actin bands (0?21, 0?27 for Nep2/2; 0?27,
0?24 for Nep-tg; 0?19, 0?23 for wt; Fig. 1d). The fact that
neither depletion nor overexpression of neprilysin seems
to influence the turnover of PrPC showed convincingly
that PrPC did not represent a substrate for the enzymic
activity of neprilysin.
Depletion of neprilysin does not alter
incubation times to terminal prion disease
Mice deficient for neprilysin (Nep2/2) and mice with
decreased levels of neprilysin expression (Nep+/2) were
challenged with various amounts of infectious prions and
the incubation time to terminal prion disease was measured.
After high-dose (36105 LD50) or low-dose (3610
2 LD50)
i.c. prion injection, there was no significant difference
in incubation times compared with wt mice (high dose:
164±4 days, n=6 for wt; 161±4 days, n=7 for Nep+/2;
165±7 days, n=7 for Nep2/2 mice; low dose: 192,
197 days, n=2 for wt; 200±17 days, n=5 for Nep+/2;
188±10 days, n=8 for Nep2/2 mice; Fig. 2).
Upon high-dose (6 logLD50) and low-dose (3 logLD50) i.p.
prion challenge, Nep2/2, Nep+/2 and wt mice developed
scrapie with similar incubation times (high dose: 208±
18 days, n=8 for wt; 211±20 days, n=15 for Nep+/2;
202±9 days, n=15 for Nep2/2 mice; low dose: 239±
10 days, n=4 for wt; 225±5 days, n=6 for Nep+/2;
242±20 days, n=9 for Nep2/2 mice; Fig. 2). These data
demonstrate clearly that prion pathogenesis and neuro-
invasion of prions are unaltered by the relative or absolute
lack of neprilysin.
The lack of an effect of neprilysin on prion pathogenesis
is further corroborated by biochemical and histological
analysis of terminally sick mice. Immunoblot analysis con-
firmed that there were comparable amounts of PrPSc in
the brains of terminally sick wt, Nep+/2 and Nep2/2 mice
(Fig. 3). We investigated the distribution of protease-
resistant PrPSc in wt, Nep+/2 and Nep2/2mice by histoblot
analysis of CNS tissue (Fig. 4). This analysis shows an even,
cortically accentuated distribution of PrPSc throughout
the entire cerebral hemispheres. Accordingly, histologi-
cal analysis of mice with complete or partial absence of
neprilysin showed unaltered patterns of vacuolization and
reactive astrogliosis within the CNS tissue when assayed
100 days following i.c. prion challenge (Fig. 5).
Fig. 1. Generation of Nep-tg mice and analysis of PrPC
expression in Nep”/” and Nep-tg mice. (a) Schematic drawing
of the DNA construct used for generation of transgenic mice.
Relevant restriction sites are indicated. The locations of primers
used to genotype transgenic mice are given as one-sided
arrows (not to scale). (b) Neprilysin expression levels were sig-
nificantly higher in total brain homogenates of mice overexpres-
sing Nep-tg compared with wt littermates. A similar preparation
of kidney total protein homogenate was loaded as a positive
control. (c) Nep enzyme activity was on average 34 times
higher in brain homogenates prepared from Nep-tg mice com-
pared with age-matched littermates (black line represents
mean, P¡0?029, Mann–Whitney U test). (d) PrPC expression
in brains of Nep”/” and Nep-tg mice, as assessed by Western
blot analysis. Equal amounts of protein were loaded, as evi-
denced by comparable intensity of b-actin bands (uppermost
band).
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Similar infectivity titres in Nep”/” and wt mice
In order to assess whether the absence of neprilysin leads
to alterations in the titre of infectious prions, we deter-
mined prion titres of CNS tissue 100 days following i.c.
prion injection by transmission of homogenized tissue
into highly prion-susceptible tga20 indicator mice (Fischer
et al., 1996) and comparison of incubation times to a
calibration curve. Infectivity in brains of Nep2/2 mice and
wt mice was comparable (Table 1). Therefore, lack of
neprilysin does not impair the kinetics of prion replication
within the CNS.
Overexpression of neprilysin does not alter CNS
prion pathogenesis
If neprilysin plays a role in degrading PrPSc, genetically
modified mice overexpressing this enzyme would be
expected to harbour decreased levels of PrPSc in their
CNS upon prion inoculation. We investigated this possi-
bility by challenging Nep-tg (n=6) and wt (n=6) mice with
infectious prions (36105 LD50, i.c. injection). All mice were
terminated 100 days following prion injection and PrPSc
levels were determined by Western blot analysis of brain
samples. Although there was some heterogeneity in the
level of PrPSc accumulation within the two groups of
mice, there was no significant difference in the level of PrPSc
accumulation between neprilysin-overexpressing and wt
mice (Fig. 6). This provides further evidence that neprilysin
is not involved in degradation of PrPSc.
DISCUSSION
Aggregation of proteins in the CNS leads to a number of
neurodegenerative diseases (Aguzzi & Haass, 2003). Lately,
Fig. 2. Incubation times in prion-inoculated Nep+/”, Nep”/” and wt mice. Survival plots displaying the incubation time (days)
until development of terminal scrapie in Nep”/” (black boxes), Nep+/” (dark-grey boxes) and wt (light-grey boxes) mice
inoculated i.p. (a, b) or i.c. (c, d) with prions. The dose of inoculum is expressed above individual graphs. There is no
significant difference in incubation times of mice inoculated either i.c. or i.p.
Fig. 3. Western blot analysis of brain tissue from terminally
scrapie-sick Nep”/”, Nep+/” and wt mice. Western blots of
CNS tissue electrophoresed before (”) or after (+) digestion
with proteinase K (PK). Similar amounts of PK-resistant prion
protein (PrPSc) were detected in the brains of Nep+/”, Nep”/”
and wt mice that had developed scrapie (terminally sick) after
the time points indicated [days post-i.c. injection (d.p.i.) of
36105 LD50 prions].
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it has become clear that, in many instances, the aggrega-
tion of misfolded proteins, which may be the cause of
dementia, is a dynamic process that is determined by a
balance of generation and clearance (Iwata et al., 2001). Both
Alzheimer’s disease and prion diseases are characterized
by extracellular accumulation of amyloidogenic proteins
(Aguzzi & Haass, 2003). Several authors have pointed to
similarities between physiological and pathological cleavage
of the amyloid-b precursor protein and the prion protein
(Checler & Vincent, 2002). Yet, whilst we understand the
processing cascade leading to deposition of amyloid-b in
Alzheimer’s disease in some detail, relatively little is known
about the equivalent processes in prion diseases (Aguzzi &
Haass, 2003; Checler & Vincent, 2002). In the case of PrPC,
physiological cleavage by ADAM10 and TACE has been
reported and it was speculated that cleavage of PrPC by
an unknown protease might result in the generation of a
toxic PrP fragment (Vincent et al., 2001). For PrPSc, the
situation is different. Cell-culture studies have shown that,
once generation of newly formed PrPSc is arrested, PrPSc
is degraded rapidly, leading to the disappearance of PrPSc
within a few days (Enari et al., 2001). Similar processes seem
to be active in vivo, leading to the generation of fragmented
PrPSc in CNS tissue of patients suffering from prion disease,
Fig. 4. Histoblot analysis of Nep”/”, Nep+/”
and wt mice following i.c. scrapie adminis-
tration. Histoblots showing immunoreactive
PrP in brains before (first column) and after
(second and third columns) digestion with
increasing concentrations of proteinase K
(50 and 100 mg ml”1). Prnp0/0 mice (first
row) do not show any signal for PrPC or
PrPSc, whereas control mice (second row)
show proteinase K-sensitive PrPC, but no
proteinase K-resistant PrPSc. The accumulation
of PrPSc in brains of terminally scrapie-sick
Nep+/+, Nep”/” and wt mice, taken 157 days
post-i.c. prion injection, is comparable.
Fig. 5. Histological analysis of brain in
Nep”/”, Nep+/” and wt mice 100 days fol-
lowing i.c. scrapie administration. Occasional
spongiform changes (a–c) and only mild
astrogliosis (d–f) were visible in the hippo-
campal neuronal ribbon of subclinically
prion-diseased Nep+/”, Nep”/” and wt mice.
GFAP, Immunohistochemical stain for the
astrocytic marker, glial fibrillary acidic pro-
tein; HE, haematoxylin/eosin stain. Bar,
50 mm.
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and it has been suggested that the alleged PrPSc-degrading
enzyme belongs to the metalloprotease family of proteoly-
tic enzymes (Jime´nez-Huete et al., 1998). In a recent study,
it was shown that cysteine proteases seem to be involved
in degradation of PrPSc in lymphoid cells and, to a lesser
extent, in neuronal cells (Luhr et al., 2004). In the same
study, metalloproteases did not seem to play a substantial
role in PrPSc degradation, raising the possibility that these
processes may be regulated in a cell-specific manner.
As a candidate, we have investigated whether neprilysin is
involved in degradation of PrPC or PrPSc. This was achieved
by subjecting genetically modified mice expressing either
reduced levels of neprilysin or no neprilysin at all and mice
overexpressing neprilysin to infectious prion preparations.
We did not find any evidence that PrPC or PrPSc represents
a target for neprilysin. On the contrary, the evidence that
neprilysin plays no role at all in prion/PrPSc is overwhelm-
ing: all investigated parameters of prion pathogenesis,
including the amount and the distribution of PrPSc in
infected brains at various time points, the amount of
infectivity in the CNS and neuropathological changes of
mid- and end-stage brains, were identical in mice lacking or
overexpressing neprilysin and wt mice.
Proteins belonging to the metalloprotease family, most of
which are expressed in CNS tissue, seem to be involved in
degradation of extracellular deposited amyloid in vivo. It has
been shown that neprilysin is the most potent amyloid-
degrading metalloprotease (Iwata et al., 2001). As neprilysin
displays a broad substrate specificity and is localized sub-
cellularly in the vicinity of PrP (Iwata et al., 2001; Turner,
2003), it is surprising that it has no impact on prion
pathogenesis.
The findings described here do not negate the involve-
ment of other metalloproteases in PrPSc catabolism. Indeed,
studies focusing on possible substrates of metalloproteases
provided evidence that matrix metalloprotease MMP-9
is able to degrade amyloid-b and might possess PrPSc-
degrading properties (Backstrom et al., 1996). The avail-
ability of reliable cell-culture models for prion diseases, in
combination with high-throughput tools to assess prion
infectivity, should significantly facilitate the investigation
of PrPSc proteolysis (Enari et al., 2001; Klo¨hn et al., 2003).
Given that our understanding of PrPSc metabolism is far
from complete, this field of prion research continues to
represent an important target for the future. In view of the
fascinating developments in Alzheimer’s disease research,
where insights into amyloid-b precursor protein process-
ing have led to the identification of the mechanisms of
amyloid-b generation and, based on this knowledge, to the
development of therapeutic strategies, the investigation of
the proteolytic cascade leading to the removal of aggregated
PrPSc might hold the key to the discovery of novel pro-
phylactic or therapeutic strategies against prion diseases
(Aguzzi & Haass, 2003).
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